BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221012T160000
DTEND;TZID=Europe/Stockholm:20221012T170000
DTSTAMP:20260419T103043
CREATED:20220920T133458Z
LAST-MODIFIED:20220923T095041Z
UID:29883-1665590400-1665594000@senzagen.com
SUMMARY:Webinar: Recap on SenzaGen’s 2022 ICT Scientific Session
DESCRIPTION:New GARD® data on agrochemicals\,”difficult-to-test” substances and potency assessments\n\n – In vitro skin sensitization testing: New opportunities for hazard and quantitative potency assessment using genomics and machine learning technology\nIn case you missed SenzaGen’s scientific session at this year’s ICT\, we are pleased to offer you a new opportunity! We will present new scientific data on agrochemical formulations generated in collaboration with Corteva Agriscience\, “difficult-to-test” substances and potency assessment. \nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \n  \n \n  \n \n  \n\nRegister now
URL:https://senzagen.com/event/webinar-recap-on-senzagens-2022-ict-industry-symposium/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/09/Recap-webinar-banner-for-website_v4-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220713T160000
DTEND;TZID=Europe/Stockholm:20220713T170000
DTSTAMP:20260419T103043
CREATED:20220630T072933Z
LAST-MODIFIED:20220825T090554Z
UID:29536-1657728000-1657731600@senzagen.com
SUMMARY:Webinar: OECD update
DESCRIPTION:Join this live webinar led by our skin sensitization specialist Dr Andy Forreryd to learn the features and benefits of GARDskin and how the method can be used to fill data gaps during regulatory testing and product development. \n \nGARDskin approved by OECD\nWe are delighted to announce that SenzaGen’s GARDskin assay has been adopted by OECD as part of Test Guideline 442E for in vitro skin sensitization\, which is a regulatory breakthrough for the GARD technology. As the first and only genomics and machine learning-based method\, GARDskin has been approved for the third key event\, dendritic cell activation. The scientific data published in the TG confirms the high performance and broad applicability of the method\, bringing new opportunities to the field of in vitro skin sensitization testing. \nThe webinar will last around 30 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \nSpeakers\n \nRegister now
URL:https://senzagen.com/event/webinar-oecd-update/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/06/LInkedIn-versaler-e1656335357210.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220525T160000
DTEND;TZID=Europe/Stockholm:20220525T170000
DTSTAMP:20260419T103043
CREATED:20220504T140953Z
LAST-MODIFIED:20220627T125525Z
UID:29411-1653494400-1653498000@senzagen.com
SUMMARY:Webinar: Medical devices' principal mode of action by physical means
DESCRIPTION:Case studies on 3D reconstructed human tissues\nThis webinar will showcase the opportunities offered by 3D reconstructed human tissues to demonstrate the physical mode of action of medical devices in line with the requirements and ethical criteria of the EU Medical Devices Regulation (MDR) 2017/745. \n\nKey takeaways\n\nAttendees will gain insights into: \n💡 How the principles of the 3Rs are applied in the MDR’s requirements. \n💡 How 3D reconstructed human tissues become a robust tool to define and demonstrate the principal mode of action of medical devices. \n💡 How to assess on a case by case approach the physical mode of action of medical devices according to their different therapeutic areas. \n  \n \nNew approach methodologies (NAMs) are driving the transition from animal testing to science-based decision-making for human risk assessment in the life sciences. This transition is aligned with EU Directive 2010/63 on the protection of animals used for scientific purposes and the principles of the 3Rs. \nWe’ll illustrate how NAMs are applied in the medical devices sector. The principles of the 3Rs were an important source of inspiration for the MDR.  ISO 10993 describing the Biological Evaluation of medical devices mandates that appropriate and scientifically validated in vitro methods be preferred over in vivo methods.  3D reconstructed human epidermis tissues can be used to assess skin irritation of medical device components and extracts (ISO 10993-23:2021). Additionally\, genomic-based test methods have been demonstrated to be promising solutions for the assessment of the skin sensitization potential of medical devices (ISO 10993-10:2021). \nManufacturers are required to provide scientific proof in their technical file for the qualification of their product as MD (MDCG 2022-5). They need to provide state-of-the-art scientific data regarding the principal mode of action of the MD. By definition\, this should be physical\, mechanical\, or chemical and cannot be pharmacological\, immunological\, or metabolic. As a result\, the demonstration of a physical mode of action became an essential requirement. The film-forming properties and bio-adhesivity of an MD can be demonstrated on 3D reconstructed human tissue models on a case-by-case approach to produce evidence of the MD’s physical mode of action. \nVitroScreen has developed and published an experimental procedure on reconstructed human epidermis for film-forming assessment. With this as a basis\, we propose protocols optimized for each specific therapeutic area by selecting the tissues on which the MD is intended to act and defining a treatment procedure that mirrors realistic conditions of use. We will present case studies based on different formulation types suitable for gastroenterology\, gynecology\, ophthalmology\, oral care\, urology\, and the respiratory tract. \n  \n\nSpeakers\n\n \n \n  \n\nRegister now
URL:https://senzagen.com/event/webinar-medical-devices-principal-mode-of-action-by-physical-means/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/05/Website-banner-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220428T160000
DTEND;TZID=Europe/Stockholm:20220428T170000
DTSTAMP:20260419T103043
CREATED:20220331T075055Z
LAST-MODIFIED:20220627T125547Z
UID:29263-1651161600-1651165200@senzagen.com
SUMMARY:Webinar: Recap on SenzaGen’s 2022 SOT Scientific Session
DESCRIPTION:New GARD® data on agrochemical formulations\, fragrance materials\, medical devices and metals\n\n – Skin sensitization: using in vitro tools for quantitative potency assessment as an alternative to the Local Lymph Node Assay\nIn case you missed SenzaGen’s scientific session at this year’s SOT\, here is a new opportunity! \nTogether with guest speakers from Takasago and Sonova\, we will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. New GARD data on agrochemical formulations\, fragrance materials\, medical devices and metals will be presented. \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \n  \n \nAgenda\n \n\nRegister now
URL:https://senzagen.com/event/webinar-recap-on-senzagens-2022-sot-exhibitor-hosted-session/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/03/Recap-webinar-banner-for-website-v5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220217T160000
DTEND;TZID=Europe/Stockholm:20220217T170000
DTSTAMP:20260419T103043
CREATED:20211209T154800Z
LAST-MODIFIED:20220204T125454Z
UID:28308-1645113600-1645117200@senzagen.com
SUMMARY:Webinar: Safer Medical Devices - In vitro assays as part of your biological evaluation
DESCRIPTION:In this webinar\, our Medical Device and ISO expert Dr Rose-Marie Jenvert will tell you more about how you can use in vitro methods for the biological evaluation of medical devices\, now offered at our GLP certified laboratories. She will also introduce you to our expanded medical device offering and how we can help you to comply with MDR. \nThe webinar will last around 45 minutes\, followed by a live Q&A. Even If you cannot attend the live event\, make sure to register to get access to the recording. \nKey topics\n\nHow you can use in vitro assays for biocompatibility testing of medical devices: cytotoxicity\, skin irritation and sensitization.\nThe broad applicability and high accuracy of the GARD sensitization assay\, supporting both polar and non-polar extraction vehicles (ISO 10993-12).\nUser cases on skin sensitization assessment of medical devices.\n\n \nSpeaker\n \n\nHighly accurate and ethical alternatives \nAn exciting evolution is ongoing in the medical device toxicology field\, transitioning from a process that largely relied on the results of animal testing to one which is increasingly focused on the use of in vitro methods for the safety assessment of medical device materials. A big step towards replacing animal testing for medical devices was taken when in vitro skin irritation testing using Reconstructed human Epidermis (RhE) tissue was implemented in the ISO 10993-23 standard published earlier this year. Moreover\, in vitro assays for skin sensitization have been included in the updated ISO 10993-10. \nIn vitro biocompatibility package \nOur GLP certified laboratories offer an in vitro biocompatibility package that includes testing of the three endpoints that need to be evaluated for all medical device products: cytotoxicity\, skin irritation and skin sensitization\, providing a solution for customers looking for a highly accurate and ethical alternative for testing of materials and medical devices. \nCytotoxicity \nThe endpoint cytotoxicity can be tested in vitro using qualitative and quantitative test methods as described in ISO 10993-5:2009 and have a history of use both for regulatory purposes and as a screening tool early in the product development phase. \nSkin irritation \nThe endpoint skin irritation using RhE-tissue according to ISO 10993-23:2021 provides human-relevant results with higher accuracy and fewer false-positive results compared to the rabbit model. \nSkin sensitization with GARD™ \nThe endpoint skin sensitization can be assessed in vitro using the GARDskin Medical Device assay\, based on a state-of-the-art technology GARD; including human immunological cells\, a specific genomic biomarker signature and a machine learning-assisted classification model. The GARDskin Medical Device assay enables the medical device industry to perform in vitro skin sensitization testing of both saline and oil extracts from devices or materials as described in ISO 10993-12 and  10993-10:2021\, thus mimicking the intended use of the device when in contact with skin.  \n\nRegister now
URL:https://senzagen.com/event/webinar-biological-evaluation-of-medical-devices-using-in-vitro-methods/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/Banner-without-logo-Cropped.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220120T160000
DTEND;TZID=Europe/Stockholm:20220120T170000
DTSTAMP:20260419T103043
CREATED:20211209T154427Z
LAST-MODIFIED:20220105T083742Z
UID:28303-1642694400-1642698000@senzagen.com
SUMMARY:Webinar: Why Choose GARD™ for Skin Sensitization Testing?
DESCRIPTION:High performance\, broad applicability\, quantitative potency\n\nJoin us for this webinar to get the latest news about the in vitro GARD assays and how they are used to fill data gaps and address challenges in skin sensitization testing\, such as “difficult-to-test” substances\, quantitative potency assessment\, testing of medical devices and solid materials. \n \nKey topics\n\nAn introduction to GARD: How the genomic and machine learning-based technology works and its applications\nCase studies: “Difficult-to-test” samples such as complex mixtures\, pre/pro- haptens and substances with low water solubility\nCase studies: In vitro skin sensitization assessment of medical devices using both saline and oil as extraction vehicles\nCase studies: In vitro quantitative potency assessment as an alternative to LLNA\n\nThe webinar will last around 40 minutes\, followed by a live Q&A. If you can’t attend the live event\, register now to get access to the recording.  \nSpeakers\n \n \n  \nRegister now
URL:https://senzagen.com/event/webinar-why-choose-gard-for-sensitization-testing-2/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/Webinar-banner-v7-cropped.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211214T160000
DTEND;TZID=Europe/Stockholm:20211214T170000
DTSTAMP:20260419T103043
CREATED:20211209T135308Z
LAST-MODIFIED:20211209T135357Z
UID:28292-1639497600-1639501200@senzagen.com
SUMMARY:SaferWorldbyDesign Webinar: Skin safety assessment according to OECD guidelines
DESCRIPTION:Join our skin sensitization expert Dr Andy Forreryd at this SaferWorldbyDesign webinar & panel discussion to learn more about skin safety assessment. \n  \nRead more and register here \n 
URL:https://senzagen.com/event/saferworldbydesign-webinar-skin-safety-assessment-according-to-oecd-guidelines/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/12/banner1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211118T160000
DTEND;TZID=Europe/Stockholm:20211118T170000
DTSTAMP:20260419T103043
CREATED:20210930T080606Z
LAST-MODIFIED:20211021T122341Z
UID:27696-1637251200-1637254800@senzagen.com
SUMMARY:Webinar: Safety Testing of Cosmetic Products
DESCRIPTION:An Overview of Established Methods and New Approach Methodologies (NAMs)\nIn this joint webinar\,  we will present an overview of established methods and New Approach Methodologies (NAMs) used in the safety testing of cosmetic products. The webinar will start with a recorded presentation followed by a live Q&A session. If you cannot attend the live event\, register now to get access to the recording. \n  \n \nKey topics and speakers\n \n\nRegister now
URL:https://senzagen.com/event/webinar-safety-testing-of-cosmetic-products/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/09/Webinar-banner-_-light-text-cropped.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211111T160000
DTEND;TZID=Europe/Stockholm:20211111T170000
DTSTAMP:20260419T103043
CREATED:20211011T163155Z
LAST-MODIFIED:20211011T163155Z
UID:27835-1636646400-1636650000@senzagen.com
SUMMARY:Webinar: Recap on SenzaGen's Eurotox Industry Symposium
DESCRIPTION:Filling data gaps in skin sensitization testing: In vitro hazard and potency assessment using GARD\nIn case you missed SenzaGen’s industry symposium at this year’s Eurotox Virtual Congress\, here is a new opportunity! Together with guest speakers from Corteva Agriscience and Essity Hygiene & Health\, we will present customer cases where the in vitro GARD assays have been successfully utilized to fill data gaps in skin sensitization hazard and potency testing. The webinar will last around 50 minutes\, followed by a live Q&A. Even If you cannot attend the live event\, register now to get access to the recording. \n  \n \nAgenda and featured speakers\n \n  \n\nRegister now\n\n 
URL:https://senzagen.com/event/webinar-recap-on-senzagens-eurotox-industry-symposium/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/10/Webinar-cover-Cropped.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211013T160000
DTEND;TZID=Europe/Stockholm:20211013T170000
DTSTAMP:20260419T103043
CREATED:20210906T094522Z
LAST-MODIFIED:20210906T123106Z
UID:27554-1634140800-1634144400@senzagen.com
SUMMARY:Webinar: Safer Medical Devices – In Vitro Assays As Part of a Biological Evaluation
DESCRIPTION:In this webinar\, the speakers will discuss the uses of in vitro assays as a part of the risk assessment and biological evaluation for the following endpoints: cytotoxicity\, skin irritation and skin sensitization. \nKey topics\nThe presentation will introduce biological evaluation and biocompatibility testing of medical devices\, with focus on in vitro assays for skin irritation and skin sensitization now implemented in the ISO 10993-23:2021 and ISO/FDIS 10993-10:2021. For assessment of skin sensitization\, the GARD™-technology will be introduced and the speakers will discuss how it can be used as a part of a biological evaluation. \nThe webinar will conclude with customer cases where in vitro assays\, including GARDskin Medical Device assay and GARDskin Dose-Response\, have been successfully utilized for risk assessment as part of the biological evaluation and for risk-based decision-making in compliance with the principles of the 3Rs throughout the product life cycle. \n  \n \nSpeakers\n  \n\nA highly accurate and ethical alternative \nAn exciting evolution is ongoing in the medical device toxicology field\, transitioning from a process that largely relied on the results of animal testing to one which is increasingly focused on the use of in vitro methods for the safety assessment of medical device materials. A big step towards replacing animal testing for medical devices was taken when in vitro skin irritation testing using Reconstructed human Epidermis (RhE) tissue was implemented in the ISO 10993-23 standard published earlier this year. Moreover\, in vitro assays for skin sensitization have been included in the updated ISO 10993-10. \nIn vitro biocompatibility package \nThe in vitro biocompatibility package includes testing of the three endpoints that need to be evaluated for all medical device products: cytotoxicity\, skin irritation and skin sensitization\, offering a solution for customers looking for a highly accurate and ethical alternative for testing of materials and medical devices. \nCytotoxicity \nThe endpoint cytotoxicity can be tested in vitro using qualitative and quantitative test methods as described in ISO 10993-5:2009 and have a history of use both for regulatory purposes and as a screening tool early in the product development phase. \nSkin irritation \nThe endpoint skin irritation using RhE-tissue according to ISO 10993-23:2021 provides human relevant results with higher accuracy and less false positive results compared to the rabbit model. \nSkin sensitization with GARD™ \nThe endpoint skin sensitization can be assessed in vitro using the GARDskin Medical Device assay\, based on a state-of-the-art technology GARD; including human immunological cells\, a specific genomic biomarker signature and a machine learning-assisted classification-model. The GARDskin Medical Device assay enables the medical device industry to perform in vitro skin sensitization testing of both saline and oil extracts from devices or materials as described in ISO 10993-12 and FDIS/ISO 10993-10:2021\, thus mimicking the intended use of the device when in contact with skin. \n\nRegister now
URL:https://senzagen.com/event/webinar-safer-medical-devices-in-vitro-assays-as-part-of-a-biological-evaluation/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/09/Banner-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210916T160000
DTEND;TZID=Europe/Stockholm:20210916T170000
DTSTAMP:20260419T103043
CREATED:20210826T102829Z
LAST-MODIFIED:20210826T142827Z
UID:27453-1631808000-1631811600@senzagen.com
SUMMARY:Webinar: How is GARD used for skin sensitization testing?
DESCRIPTION:User cases on hazard and potency assessment\nGiven the huge interest in our previous webinar on GARD user cases\, we are pleased to offer you a new opportunity to hear how our customers use GARD to fill data gaps in sensitizing hazard and potency assessment of chemicals and medical devices. \n\nKey topics\nWe will provide several user cases on how the GARD assays have been used for skin sensitization testing to demonstrate: \n\nHazard assessment of “difficult-to-test” samples such as complex mixtures and surfactants.\nSensitization information for risk assessment of medical devices and solid materials.\nPotency determination for both CLP classification and product development.\n\nThe webinar should last around 40 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording of this webinar. \nSpeakers\n  \n\nRegister now
URL:https://senzagen.com/event/new-opportunity-how-is-gard-used-for-sensitization-testing/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/08/webinar-banner-cropped.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210601T160000
DTEND;TZID=Europe/Stockholm:20210601T170000
DTSTAMP:20260419T103043
CREATED:20210525T093936Z
LAST-MODIFIED:20210525T094123Z
UID:27136-1622563200-1622566800@senzagen.com
SUMMARY:SaferWorldbyDesign Webinar: A novel in vitro approach for quantitative assessment of skin sensitizing potency
DESCRIPTION:This presentation will introduce GARDskin Dose-Response assay\, a novel approach for the assessment of relative skin sensitizing potency on a continuous scale. \nResults demonstrate that induction of toxicity pathways in GARDskin Dose-Response appears to be highly dose-dependent\, and the lowest concentration required to induce a positive classification in the assay correlates strongly and significantly with both LLNA EC3 and human NOEL values. \nA case study will be used to illustrate how the experimentally derived values from the GARDskin Dose-response assay can be used for CLP potency assessments\, potency rankings of potential candidate molecules\, or as a point of departure for quantitative risk assessment without having to revert to animal experimentation. \nFeatured Speakers\n\nAndy Forreryd\, PhD \nDr Andy Forreryd holds a Master of Science in molecular biotechnology from the Faculty of Engineering LTH at Lund University and a Doctor of philosophy in Immunotechnology from Lund University. He has many years of experience working with in vitro assay development\, genomics\, and machine learning. He is co-developer of the GARD® platform for the assessment of chemical sensitizers and inventor of two patents related to the technology. \n  \nRead more and register here
URL:https://senzagen.com/event/saferworldbydesign-webinar-a-novel-in-vitro-approach-for-quantitative-assessment-of-skin-sensitizing-potency/
CATEGORIES:Webinar
END:VEVENT
END:VCALENDAR